Gaona Isabella P, McCall A Scott, Geis Natalie M, Colvard Arlo C, DiGiovanni Gianluca T, Sherrill Taylor P, Singha Ujjal K, Nichols David S, Serezani Anna P, David Holly E, Cartailler Jean-Philippe, Shrestha Shristi, Gutor Sergey S, Blackwell Timothy S, Kropski Jonathan A, Gokey Jason J
Division of Allergy, Pulmonary, and Critical Care Medicine, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN 37232, USA.
Department of Veterans Affairs Medical Center, Nashville, TN 37212, USA.
bioRxiv. 2025 Jul 18:2025.07.16.665213. doi: 10.1101/2025.07.16.665213.
YAP/TAZ signaling is required for initiation of lung alveolar repair, yet previous studies in idiopathic pulmonary fibrosis (IPF) predicted increased YAP/TAZ signaling in alveolar epithelial cells (AECs). We investigated whether persistent YAP/TAZ AEC signaling contributes to failed epithelial repair and persistent fibrotic remodeling. In IPF lungs, we identified increased YAP/TAZ AECs and increased expression of YAP/TAZ transcriptional targets compared to donor control lungs. In human lung organoids, pharmacological YAP/TAZ activation resulted in phenotype shifts of AECs into aberrant transitional states. In mice with Yap/Taz activation (YT) resulting from deletion of Hippo-kinases Stk3/4 in alveolar-type 2 (AT2) cells, resulted in persistent fibrotic remodeling at 28- and 56-days post-bleomycin injury. Gene promoter activity associated with transitional cell markers ( and ) was increased in YT AT2 cells. Immunofluorescent staining showed a loss of AT2 associated Cebpa and increased in YT lineage traced AT2 cells 28 days post-injury. Inhibition of Yap/Taz using Verteporfin resulted in improved lung repair in YT mouse lungs, including increased Cebpa and decreased transitional cells. These findings demonstrate sustained Yap/Taz activation drives abnormal alveolar repair and persistent fibrotic remodeling. Blocking aberrant persistent Yap/Taz activity promotes adaptive repair and has potential as a therapeutic strategy for PF.
YAP/TAZ信号传导是肺泡修复启动所必需的,但先前关于特发性肺纤维化(IPF)的研究预测肺泡上皮细胞(AEC)中YAP/TAZ信号传导会增强。我们研究了持续的YAP/TAZ AEC信号传导是否会导致上皮修复失败和持续性纤维化重塑。在IPF肺组织中,与供体对照肺相比,我们发现YAP/TAZ AEC增加,且YAP/TAZ转录靶点的表达也增加。在人肺类器官中,YAP/TAZ的药理学激活导致AECs表型转变为异常过渡状态。在因肺泡2型(AT2)细胞中Hippo激酶Stk3/4缺失而导致Yap/Taz激活(YT)的小鼠中,博莱霉素损伤后28天和56天出现持续性纤维化重塑。与过渡细胞标志物相关的基因启动子活性在YT AT2细胞中增加。免疫荧光染色显示,损伤后28天,YT谱系追踪的AT2细胞中与AT2相关的Cebpa丢失,且 增加。使用维替泊芬抑制Yap/Taz可改善YT小鼠肺的修复,包括增加Cebpa和减少过渡细胞。这些发现表明,持续的Yap/Taz激活会驱动异常的肺泡修复和持续性纤维化重塑。阻断异常持续的Yap/Taz活性可促进适应性修复,并具有作为PF治疗策略的潜力。